

# Wonkyung Byon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10266333/publications.pdf>

Version: 2024-02-01

10  
papers

830  
citations

1040056

9  
h-index

1372567

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

1038  
citing authors

#	ARTICLE	IF	CITATIONS
1	Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 615-631.	2.2	8
2	Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY. <i>Advances in Therapy</i> , 2021, 38, 3003-3018.	2.9	19
3	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. <i>Circulation</i> , 2020, 141, 1384-1392.	1.6	87
4	Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1265-1279.	3.5	174
5	Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 728-738.	2.5	49
6	Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 637-645.	2.0	141
7	Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 119-127.	2.2	87
8	Reporting guidelines for population pharmacokinetic analyses. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 875-887.	2.0	11
9	Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 908-916.	2.4	234
10	Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. <i>Clinical Pharmacology: Advances and Applications</i> , 2013, 5, 59.	1.2	20